Association between the PPARG gene polymorphism and the risk of diabetic nephropathy: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 5, 2012, Pages 429-434

  Yu, Ruichao ^a   Bo, Hong ^a   Huang, Songming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ARTICLE; ASIA; DATA BASE; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; PUBLICATION; QUANTITATIVE ANALYSIS; RACE;

ASIAN CONTINENTAL ANCESTRY GROUP; DIABETIC NEPHROPATHIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS;

EID: 84861499222     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0242     Document Type: Article

References (35)

1. Balakumar P, Arora MK, Singh M. (2009) Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 60:170-173.
2. Caramori ML, Canani LH, Costa LA, et al. (2003) The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52:3010-3013.
3. Cha DR, Zhang X, Zhang Y, et al. (2007) Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56:2036-2045.
4. Collins AJ, Kasiske B, Herzog C, et al. (2007) Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 49:A6-7, S1-296.
5. Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287.
6. Erdogan M, Karadeniz M, Eroglu Z, et al. (2007) The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 78:355-359.
7. Fujisawa T, Ikegami H, Kawaguchi Y, et al. (1998) Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41:47-53.
8. Gayathri SB, Radha V, Vimaleswaran KS, et al. (2010) Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41). Metab Syndr Relat Disord 8:119-126.
9. Gouda HN, Sagoo GS, Harding AH, et al. (2010) The association between the peroxisome proliferator-activated receptorgamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 171:645-655.
10. Gross P, Pistrosch F. (2007) PPAR agonists in diabetic nephropathy. Nephrol Dial Transplant 22: 2095.
11. Herrmann SM, Ringel J, Wang JG, et al. (2002) Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51:2653-2657.
12. Huang X, Zhao J, Zhao T. (2011) Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis. Atherosclerosis 215:136-144.
13. Jorsal A, Tarnow L, Lajer M, et al. (2008) The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab 94:347-351.
14. Lapice E, Pinelli M, Riccardi G, et al. (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 33:e114.
15. Li Y, Tang K, Zhang Z, et al. (2011) Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a metaanalysis. Mol Biol Rep 38:3243-3252.
16. Lin CC, Wu CT, Wu LS. (2011) Ectonucleotide pyrophosphatase/ phosphodiesterase 1 K173Q polymorphism is associated with diabetic nephropathy in the Taiwanese population. Genet Test Mol Biomarkers 15:239-242.
17. Little J, Higgins JP, Ioannidis JP, et al. (2009) Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 125:131-151.
18. Liu L, Zheng T, Wang F, et al. (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33:144-149.
19. Moczulski DK, Rogus JJ, Antonellis A, et al. (1998) Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 47:1164-1169.
20. Ng DP, Tai BC, Koh D, et al. (2005) Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48:1008-1016.
21. Park CW, Kim HW, Ko SH, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55:885-893.
22. Pei D, Huang YJ, Hsieh CH, et al. (2010) The genetic background difference between diabetic patients with and without nephropathy in a Taiwanese population by linkage disequilibrium mapping using 382 autosomal STR markers. Genet Test Mol Biomarkers 14:433-438.
23. Pollex RL, Mamakeesick M, Zinman B, et al. (2007) Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 21:166-171.
24. Sale MM, Smith SG, Mychaleckyj JC, et al. (2007) Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes 56:2638-2642.
25. Seaquist ER, Goetz FC, Rich S, et al. (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165.
26. Szeto CC, Chow KM, Poon PY, et al. (2008) Peroxisome proliferator- activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. Am J Nephrol 28:715-722.
27. Tang SC, Leung JC, Chan LY, et al. (2006) Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 17:1633-1643.
28. Tonjes A, Scholz M, Loeffler M, et al. (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489-2497.
29. Wen MJ, Lin CJ, Hung YJ, et al. (2011) Association study between apolipoprotein E gene polymorphism and diabetic nephropathy in a Taiwanese population. Genet Test Mol Biomarkers 10.1089/gtmb.2010.0201.
30. Wu LS, Hsieh CH, Pei D, et al. (2009) Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 24:3360-3366.
31. Xu W, Li Y, Wang X, et al. (2010) PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol Rep 24:579-585.
32. Zang HL, Wang CJ, Yang JC. (2010) [The protective role of PPARgamma in diabetic nephropathy]. Sheng Li Ke Xue Jin Zhan 41:435-438.
33. Zhang Y, Guan Y. (2005) PPAR-gamma agonists and diabetic nephropathy. Curr Diab Rep 5:470-475.
34. Zintzaras E, Stefanidis I. (2005) Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 50:84-91.
35. Zintzaras E, Uhlig K, Koukoulis GN, et al. (2007) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. J Hum Genet 52:881-890.